Health
Radiopharmaceutical experts advocate for bolder dosing despite safety setbacks
Proponents of the targeted radiation therapies believe more frequent dosing could improve cancer treatment, but recent trials have faced safety issues.
The short version
- Medical experts, including industry leader Louise Emmett, argue that pharmaceutical developers are dosing new radiopharmaceutical cancer therapies too conservatively.
- Advocates believe more frequent dosing could destroy cancer cells more effectively and prolong patient survival.
- The push for bolder dosing comes amid recent clinical setbacks, where experimental therapies inadvertently damaged patients' kidneys, liver, or bone marrow, leading to at least one company closure.
Key facts
- Radiopharmaceuticals represent a modern approach to oncology by delivering targeted radiation directly to cancer cells.[STAT]
- Louise Emmett, a prominent expert collaborating with major drugmakers like AstraZeneca and Novartis, argues that the pharmaceutical industry is dosing these therapies too timidly.[STAT]
- Over the past five years, some experimental radiopharmaceutical treatments have caused unintended safety issues, damaging patients' kidneys, liver, or bone marrow.[STAT]
- These adverse safety profiles have disrupted operations at several organizations and forced at least one radiopharmaceutical company to shut down recently.[STAT]
What remains uncertain
- It remains unclear how drug developers will balance the push for more aggressive dosing frequencies with the documented risks to vital organs like the kidneys and liver.[STAT]